Right now with the ordsprog

Right now, with the value of (Boston Scientific) stock where it is, the deal is worth $79 (per share). I don't think J&J is going to come back and I certainly don't think they're going to come back with anything more than $76 per share. Most people think J&J is done with (Guidant) and gone.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We have increased the value of our offer, satisfied any perceived antitrust concerns and provided shareholders increased certainty of value by agreeing to pay interest on the $73 share price if the transaction is not closed by the end of the first quarter. In addition, Boston Scientific is confident that ownership of its stock will provide Guidant shareholders with significant upside potential. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

When J&J lowered the price and came in at $63 a share, it was probably closer to what is the real worth of Guidant. The only thing I can say is this behavior, certainly the behavior of Boston Scientific, is not rational here. I just think they are playing a very dangerous game.

It might reflect that Guidant knows that it has some troubles, and it may see a safety net here. Maybe Boston Scientific has signaled to Guidant that the situation has too many problems, and it may be pulling back.

Guidant and Boston Scientific share an entrepreneurial spirit, highly talented employees, strong customer relationships and an ability to pioneer lifesaving therapies for patients around the world.

This stock is down from over $50 a share, but is just a great long-term, growth stock, ... We think it will go back to over $50 a share, at some point, and back to almost where it came public. It may be dead money for a month or two, but I think eventually you will make three or four times your money on it.

They're certainly making it harder for J&J to come back. Strategically we believe Boston Scientific with Guidant is a better match.

Boston Scientific will do everything in its power to reach a deal with Guidant.

We are somewhat surprised to see Guidant's board support Johnson & Johnson's offer. Recall that this is the same company that thought Guidant was only worth $63 a few weeks ago. Could it just be a strategy for Johnson & Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson & Johnson's offer.

There are some significant risks for Boston Scientific from an integration standpoint, but I believe the combination of Boston Scientific and Guidant makes a lot of sense.

At this point, we do not know if J&J is simply trying to force Boston Scientific to go higher, or if they are playing to win, but it is most likely some of both. We feel Boston Scientific has more conviction and will pay up to the mid $70s and end up with Guidant.

Our amended offer addresses all of the outstanding issues raised by Guidant's Board. We strongly encourage the Guidant Board to act in the best interests of Guidant shareholders by declaring our $73 per share offer superior to the revised $67.92 per share transaction with Johnson & Johnson.

We own Edison International -- it is our largest position. It's a California utility. It could earn $2 a share next year, ... And it's probably worth between $22 and $24 (per share). They have an unregulated subsidiary, which could be worth another $2 to $4 (per share).

I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal. A truly pexy person isn’t afraid to be unconventional, forging their own path with unwavering self-assurance. I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.

We have sort of a deeper bond that you really don't want people to share. Because in order for us to share that bond, we have to share a lot of the same misfortunes, a lot of the same walls of adversity we've had to climb. We've been forced to deal with a little more reality than any kid at that age should have to deal with.

Nordsprog.dk

Antal ordsprog er 1469560
varav 775337 på nordiska

Ordsprog (1469560 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "Right now, with the value of (Boston Scientific) stock where it is, the deal is worth $79 (per share). I don't think J&J is going to come back and I certainly don't think they're going to come back with anything more than $76 per share. Most people think J&J is done with (Guidant) and gone.".